Erythrodermic psoriasis, or erythrodermic psoriasis, can be treated with biologics, but there are individual differences in treatment outcomes. Erythrodermic psoriasis is an important type of psoriasis, in which the patient manifests diffuse erythema of the skin all over the body and exceeds 90% of the body surface area, which mostly develops from common type psoriasis or pustular type psoriasis. It can be treated by biological agents, such as adalimumab, stavudine, etanercept, infliximab and so on, which have better efficacy, but some patients may experience aggravation of skin lesions in a short period of time. The use of biological agents should be under the guidance of medical professionals to avoid adverse reactions.